CoChat

The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease

Open access
on behalf of the Centers for Disease Control and Prevention CKD Initiative, Yarnoff, Benjamin O., Hoerger, Thomas J., Simpson, Siobhan K., Leib, Alyssa, Burrows, Nilka R., Shrestha, Sundar S., Pavkov, Meda E. · 2017 · BMC Nephrology

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Better treatment during early stages of chronic kidney disease (CKD) may slow progression to end-stage renal disease and decrease associated complications and medical costs. Achieving early treatment of CKD is challenging, however, because a large fraction of persons with CKD are unaware of having this disease. Screening for CKD is one important method for increasing awareness. We examined the cost-effectiveness of identifying persons for early-stage CKD screening (i.e., screening for moderate albuminuria) using published CKD risk scores. METHODS: We used the CKD Health Policy Model, a micro-simulation model, to simulate the cost-effectiveness of using CKD two published risk scores by Bang et al. and Kshirsagar et al. to identify persons in the US for CKD screening with testing for albuminuria. Alternative risk score thresholds were tested (0.20, 0.15, 0.10, 0.05, and 0.02) above which persons were assigned to receive screening at alternative intervals (1-, 2-, and 5-year) for follow-up screening if the first screening was negative. We examined incremental cost-effectiveness ratios (ICERs), incremental lifetime costs divided by incremental lifetime QALYs, relative to the next higher screening threshold to assess cost-effectiveness. Cost-effective scenarios were determined as those with ICERs less than $50,000 per QALY. Among the cost-effective scenarios, the optimal scenario was determined as the one that resulted in the highest lifetime QALYs. RESULTS: ICERs ranged from $8,823 per QALY to $124,626 per QALY for the Bang et al. risk score and $6,342 per QALY to $405,861 per QALY for the Kshirsagar et al. risk score. The Bang et al. risk score with a threshold of 0.02 and 2-year follow-up screening was found to be optimal because it had an ICER less than $50,000 per QALY and resulted in the highest lifetime QALYs. CONCLUSIONS: This study indicates that using these CKD risk scores may allow clinicians to cost-effectively identify a broader population for CKD screening with testing for albuminuria and potentially detect people with CKD at earlier stages of the disease than current approaches of screening only persons with diabetes or hypertension.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12882-017-0497-6

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart of CKD screening and treatment in the CKD health policy model. ACE, angiotensin-converting enzyme inhibitor; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; GFR, glomerular filtration rate
Fig. 1 Flowchart of CKD screening and treatment in the CKD health policy model. ACE, angiotensin-converting enzyme inhibitor; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; GFR, glomerular filtration rateCC BY · PubMed Central
Fig. 2 Sensitivity of results to 25% changes in specific parameters for screening and treatment, using a risk threshold of 0.02 for the Bang et al. risk score with 2-year follow-up screening relative to no screening. ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate
Fig. 2 Sensitivity of results to 25% changes in specific parameters for screening and treatment, using a risk threshold of 0.02 for the Bang et al. risk score with 2-year follow-up screening relative to no screening. ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rateCC BY · PubMed Central
Fig. 3 Sensitivity of results to 25% changes in specific parameters for screening and treatment, using a risk threshold of 0.05 for the Kshirsagar et al. risk score with 2-year follow-up screening relative to no screening. ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate
Fig. 3 Sensitivity of results to 25% changes in specific parameters for screening and treatment, using a risk threshold of 0.05 for the Kshirsagar et al. risk score with 2-year follow-up screening relative to no screening. ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rateCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 35 references

Research works printed but not linked: 1

  1. Weinstein M, Siegel J, Gold M, Kamlet M, Russell L. Cost-effectiveness in heath and medicine. New York: Oxford University Press; 1996.

Cited by

See all 57

Metadata

Authors
Initiative, O. B. O. T. C. F. D. C. A. P. C., Yarnoff, B. O., Hoerger, T. J., Simpson, S. K., Leib, A., Burrows, N. R., Shrestha, S. S., & Pavkov, M. E.
Affiliations
  • RTI International (US)
  • Centers for Disease Control and Prevention (US)
Corresponding author
Yarnoff, Benjamin O.
Venue
BMC Nephrology
Published
2017-03-13
Volume
18
Issue
1
Pages
85-85
ISSN
1471-2369 (ISSN-L)
OpenAlex
W2595986895
Cited by
55
References
36
Citations by year
2026: 3 · 2025: 11 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 4 · 2020: 9 · 2019: 3 · 2018: 2
FWCI
6.89
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Nephrology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Centers for Disease Control and Prevention (200-2008-27958)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
chronic kidney disease, CKD screening, albuminuria, cost-effectiveness, screening thresholds, quality-adjusted life years, early detection
MeSH terms
Adult, Aged, Albuminuria, Cost-Benefit Analysis, Female, Humans, Male, Mass Screening, Middle Aged, North Carolina, Sensitivity and Specificity, Reproducibility of Results, Comorbidity, Prevalence, Health Care Costs, Cost of Illness, Risk Assessment, Early Diagnosis, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. https://app.cochat.ai/papers/10.1186/s12882-017-0497-6
The paper
Initiative, O. B. O. T. C. F. D. C. A. P. C., Yarnoff, B. O., Hoerger, T. J., Simpson, S. K., Leib, A., Burrows, N. R., Shrestha, S. S., & Pavkov, M. E. (2017). The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrology. https://doi.org/10.1186/s12882-017-0497-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.